Data Projects Further Growth for the Legal Cannabis and CBD Markets

Monday, November 27, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, November 27, 2017 /PRNewswire/ --

According to Grand View

Research, the global medical cannabis market is expected to reach USD 55.8 billion by 2025. Increasing use of cannabis for medical purposes is one of the key factors that drives the market. The CBD market is projected to
experience rapid growth in the cannabis industry due to its medical benefits, which are highly in demand. According to a report published by Hemp Business Journal, the CBD consumer market is expected to reach $2.1 billion by 2020., Inc. (OTC: CIIX), Terra Tech Corp. (OTC: TRTC), Cannabis Science, Inc. (OTC: CBIS), WEED, Inc. (OTC: BUDZ), Aurora Cannabis Inc. (OTC: ACBFF)

Hemp Business Journal Founder and Publisher, Sean Murphy, explained, "The CBD Report is the culmination of more than a year of focused market research. We've been to Israel, Europe, Canada and to farms, labs and retailers across the U.S. to cover the hemp industry. By analyzing consumer sales in the hemp and marijuana industries, we've provided the first view to investors, executives and regulators on what's really happening with CBD, the hottest category in the broader multi-billion dollar cannabis industry.", Inc. (OTCQB: CIIX) announced breaking news on November 21st that, "Its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., has teamed up with Chinese beauty influencer, The Godfather of Beauty, for the launch of its "CBD Magic Hemp Series" skincare line on China's largest e-commerce retailer Alibaba. Within minutes of its launch on the 'China Taobao Live Broadcasting Celebrity Show', over 91 units from the CBD Magic Hemp Series skincare line were purchased by excited consumers, with over 40,000 views during the first broadcast. See broadcast at

Taobao, part of the Alibaba Group, is the largest shopping site in Asia with upwards of 500 million registered users. With years of experience in live, online marketing on the Taobao Platform, "The Godfather of Beauty is an Internet celebrity with over 60,000 active followers. Through its partnership with Taobao and with The Godfather of Beauty, the Company has an amazing opportunity to expand its e-commerce presence in China through live product demonstrations and social interaction with fans."

"It is well documented that ancient Chinese recognized the medicinal properties of the hemp plant. Now this ancient remedy is re-emerging in the Chinese skincare industry and CBD Biotechnology Co. Ltd. is pleased to be among the first to bring such a novel skincare line to market," says Warren Wang, CEO of, Inc. "The success of the initial launch of the CBD Magic Hemp Series skincare line on Taobao solidifies our belief that Chinese consumers recognize that the anti-inflammatory agents and anti-oxidants contained in hemp-extract can have positive effects on the skin."

"We are excited about the Company's partnerships with Taobao and The Godfather of Beauty and are pleased with consumer reaction to the initial launch and product," says CBD Biotechnology Co. Ltd. CEO, Summer Yuan. "China is the second largest cosmetics consumer market in the world with a market size of more than 300 billion CNY, or roughly 45 billion USD. With such a large consumer audience, we see huge possibilities for continued growth and plan to continue to develop new, innovative products for the Chinese market and will continue to partner with dynamic influencers throughout mainland China to spread the word about the CBD Magic Hemp Series product line. We anticipate explosive growth in the coming year."

Terra Tech Corp. (OTCQX: TRTC) recently provided an update on the planned joint venture with NuLeaf Sparks Cultivation LLC and NuLeaf Reno Production LLC, in Nevada, which was announced on August 30, 2017. A wholly-owned subsidiary of Terra Tech has made a convertible loan to NuLeaf Sparks, and a convertible loan to NuLeaf Reno, both of which will automatically convert to 50% ownership of the NuLeaf entities upon approval by the State of Nevada. The joint venture is expected to fast track Terra Tech's cultivation and production facilities, allowing it to increase supply of its proprietary IVXX wholesale brand to meet the growing demand for cannabis products throughout Nevada.

Cannabis Science, Inc. (OTC: CBIS) that its expansions plans are well underway as it has signed agreements to acquire and officially open the first Cannabis Science PRE ICO Medical Marijuana dispensary, in Los Angeles, California. "Attaining this first PRE ICO Dispensary in L.A. is a huge step for Cannabis Science as it opens the door to speed up our planned expansion in the Los Angeles area and eventually California statewide," stated Cannabis Science Inc., President & CEO, Co-Founder, Mr. Raymond C. Dabney. "This is a prime example of our resilient and aggressive negotiations to acquire multiple pharmacies across the Los Angeles area. Finalizing this acquisition is just the first step of many that Cannabis Science will be taking to establish a statewide presence, with a nationwide future goal."

WEED, Inc. (OTC: BUDZ) is a multi-national, multi-faceted, vertically integrated World Class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly owned subsidiaries and strategically placed collaborative partners to achieve & promote our Global Brand. WEEDs plans commence with extensive background research into the biomedical and phytochemical applications and Cannabis related treatments focused on the human endo-cannabinoid system, more specifically, targeted research into genomics, metabolomics, phytochemicals and secondary metabolites in both Australia and the USA, will result in the production of the required scientifically valid, evidence based, cannabis strains and identification and production of disease specific medicines.

Aurora Cannabis Inc. (OTCQX: ACBFF) it has formally commenced its offer (the "Offer") to purchase all of the issued and outstanding common shares of CanniMed Therapeutics Inc. for consideration consisting of common shares of Aurora. Notice and advertisement of the Offer was placed in the November 24, 2017 edition of the Globe & Mail, and a takeover bid circular will be mailed to CanniMed shareholders. In addition, Aurora will file the offer and takeover bid circular and related documents on SEDAR. The Offer Documents will also be available on Aurora's website at and shareholders are invited to visit for further information.

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions, recommendations or commentary. For this release, expects to be compensated three thousand dollars for financial news dissemination and PR services by Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a two year agreement with Inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, and quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information: Media Contact: +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store